In addition, in muscle-infiltrating bladder cancer cells, knockdown of MSH2 reduced cellular sensitivity to cisplatin, and low MSH2 expression was associated with lower survival in patients treated with cisplatin (Henrique et al. 2019). This evidence concerns the gene MSH2 and urinary bladder cancer.